Gene Therapy for Rare Disorders Europe London, England, UK 31 October - 2 November, 2017

Description:
Gene Therapy for Rare Disorders Europe is devoted to overcoming these challenges, focusing specifically on the clinical, manufacturing, regulatory and reimbursement hurdles that need to be overcome for gene therapies to reach their full potential.

Uniting leaders from Pfizer, GSK, Shire and uniQure, this meeting focusses specifically on delivering practical insights into developing the next generation of gene therapies that promise improved efficacy, enhanced safety and commercial viability.

Join your colleagues at this uniquely focused event and discover how to enhance every stage of your gene therapy development to achieve commercial success.

Prices do not include VAT. Email info@hansonwade.com for an Academic rate.

Booking: https://go.evvnt.com/155837-0
Brochure: https://go.evvnt.com/155837-1

Price
Conference Earlybird (Book by 22/09/17): GBP 1799
Conference + 1 Workshop Earlybird (Book by 22/09/17): GBP 2298
Workshop only: GBP 599
Conference (Standard rate): GBP 1999
Conference + 1 Workshop (Standard rate): GBP 2498

Speakers: Sven Kili (GSK), Wim Scheele (Pfizer), Detlev Parow (DAK), Sander van Deventer (uniQure), Christiane Niederlaender (UK Medicines and Healthcare Products Regulatory Agency (MHRA)), Aniz Girach (NightstarX), Hanspeter Rottensteiner (Shire), Jean-Philippe Combal (Vivet Therapeutics), Adrien Lemoine (Orchard Therapeutics)

Time: on Tuesday October 31, 2017 at 1:00 pm (ends Thursday November 02, 2017 at 4:30 pm)